1. Home First Finance Company India:
Motilal Oswal reiterates its ‘Buy’ call on this housing finance company, with a target price of Rs 1,425, an upside of 28.6%. Analysts Abhijit Tibrewal and Nitin Aggarwal cite strong loan growth, better collections, and stable margins. Home First posted a healthy Q4FY26 performance: profit rose 43% YoY, and net interest income grew 37%. Assets under management (AUM) increased 25% to Rs 15,900 crore, helped by strong disbursements and steady spreads.
Management says the company is starting FY27 on a stronger footing. It appears to have fixed earlier issues with employee turnover and collections. The company plans to add 30–40 branches in FY27 and expand in existing markets. It continues to focus on affordable housing and clarified that larger loan sizes are due to rising property prices, not riskier lending.
Tibrewal and Aggarwal believe the company is a steady ship, and is in a great position to keep growing. Its focus on affordable housing, careful lending, and stable loan quality will support earnings. They expect the company's loan portfolio (AUM) to grow 23% annually and its net profit to grow 18% annually over the next two years.
2. Aadhar Housing Finance:
It looks like analysts are preferring the housing finance space in today’s volatile market. IDBI Capital reiterates its ‘Buy’ rating on this housing finance provider, with a target price of Rs 602, implying an upside of 23.5%. Aadhar Housing posted robust Q4FY26 results, where its revenue climbed 19% YoY, and net profit jumped 27%, boosted by higher loan disbursements, increased assets under management (AUM), affordable housing expansion, and stable asset quality.
Analysts Sweta Padhi and Smit Shah point to continued housing demand, healthy operating leverage, and stable asset quality for its strong outlook and earnings growth. The company continues to benefit from its granular, secured retail portfolio and improving operating efficiency. Its cost-to-income ratio should decline further. Management affirmed their guidance: 20% AUM and net profit growth each, and 17-18% higher disbursements over the medium-term.
Padhi and Shah noted that management’s shift toward emerging regional markets and self-employed borrowers helps yield expansion, while AI-led underwriting and collections improve productivity. With stable margins and consistent earnings visibility, the company is well-positioned for compounding. Disciplined risk management and strong distribution expansion support this. They expect the company to deliver a net interest income CAGR of 20.7% through FY28.
3. Polycab India:
Prabhudas Lilladher maintains its ‘Buy’ rating on this wires & cables manufacturer, with a higher target price of Rs 10,282, a 14% upside. Polycab reported healthy Q4FY26 results: revenue jumped 26.9% YoY, and net profit rose 6.3%. Analysts Praveen Sahay and Shivam Patel noted that strong cable demand and execution drove top-line and profit growth, despite softer trade sentiment and Middle East disruptions.
Cables outperformed wires during the quarter, while institutional sales grew faster than channel sales. Analysts added that volume growth remained low, impacted by construction halts in North & West India, geopolitical disruptions, and softer secondary sales. However, cumulative price hikes of 18-19% during the quarter helped higher realisations.
Management highlighted a robust medium-term demand outlook, with significant capital expenditure in utilities, renewables, data centres, manufacturing, railways, and infrastructure. Exports are also expected to become a key growth driver. They plan Rs 6,000-8,000 crore in capex over the next five years, allocating ~90% to wires & cables, ~5% to backward integration, and the rest to fast-moving electrical goods. Sahay and Patel expect Polycab to deliver about 20.1% revenue and net profit CAGRs through FY28, fueled by improved margins and stronger sales momentum.
4. Emcure Pharmaceuticals:
BOB Capital Markets maintains its ‘Buy’ rating on this pharma company, with a target price of Rs 1,965, an upside of 18.6%. Analyst Foram Parekh remains positive as Emcure continues to deliver strong international growth, margin improvement, and expansion in specialised medicines in regulated countries such as Europe and Canada. Higher shipping and material costs from Middle East tensions are a short-term risk. However, the company has enough inventory to handle disruptions for the next 3-6 months.
Emcure posted strong Q4FY26 results. Revenue grew 16.7% YoY, driven by robust growth in Europe, Canada, and emerging markets. Management forecasts revenue growth in the low-to-mid teens for FY27. They also expect EBITDA margins to improve by 75-100 basis points. The company expects its domestic business to outpace the industry. It is also adding new products through partnerships with Sanofi and Roche for diabetes and kidney treatments.
Parekh predicts international business will keep growing in the mid-teens. This growth comes from new drugs, a partnership in Canada, and strong demand for anti-retroviral treatments. She forecasts revenue to grow 13% annually, EBITDA 18%, and net profit 24% from FY27-29.
5. Tata Consumer Products:
ICICI Direct retains its ‘Buy’ call on this tea & coffee producer, with a target price of Rs 1,420, an upside of 13.3%. Tata Consumer reported strong Q4FY26 results: revenue jumped 17.6% YoY, and net profit climbed 21.5%, thanks to growth across segments and lower tea input costs.
Analysts Kaustubh Pawaskar and Abhishek Shankar believe its growth businesses, new Organic Foods acquisition, and a recovery in capital foods will drive future revenue. The company is seeing healthy growth in its Tata Sampann brand, helped by new product launches. A new diversified distribution strategy also boosted sales of its premium products. Management is guiding for double-digit revenue growth in FY27.
Pawaskar and Shankar noted that tea prices have corrected from their highs and should remain stable in FY27, while coffee price correction benefits will be effective from Q1FY27. They expect the company to deliver a revenue CAGR of 13% and a net profit CAGR of 21% over FY27-28.
Note: These recommendations are from various analysts and are not recommendations by Trendlyne.
(You can find all analyst picks here)
